| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Santosh Shantilal Vora CEO | MSE Exchange | INE0JWS01017 ISIN |
| IN Country | 79 Employees | - Last Dividend | - Last Split | - IPO Date |
Valiant Laboratories Limited, formerly known as Bharat Chemicals, is a prominent active pharmaceutical ingredient (API) and bulk drug manufacturing company with a global footprint. Founded in 1980 and headquartered in Mumbai, India, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products to meet various medicinal needs. It operates both within India and internationally, showcasing a significant presence across multiple continents. In August 2021, the company underwent a rebranding from Bharat Chemicals to Valiant Laboratories Limited, marking a new chapter in its journey towards pharmaceutical excellence. As a subsidiary of Dhanvallabh Ventures LLP, Valiant Laboratories continues to grow and expand its operations, maintaining a strong focus on quality, innovation, and customer satisfaction.
Valiant Laboratories Limited specializes in the manufacture of paracetamol, a widely used analgesic and antipyretic drug. The company offers paracetamol in various grades, including those compliant with Indian, British, European, and United States pharmacopeias. This ensures that Valiant Laboratories' paracetamol meets the highest standards of quality and safety, catering to diverse market requirements. It is effective for the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fevers, making it a versatile solution for pain and fever reduction.
In addition to pharmaceuticals, Valiant Laboratories Limited offers a range of specialty chemicals. These chemicals are designed for various industrial applications and are produced with the same commitment to quality and innovation that characterizes the company's pharmaceutical offerings. The specifics of these specialty chemicals and their applications demonstrate Valiant Laboratories' capability to diversify its product range and meet the evolving needs of its clients beyond the pharmaceutical sector.